Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 3:33 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 457–480 of 2,665 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Control II Clear all
Completed Phase 2 Interventional

Study Evaluating the Safety and Efficacy of MEGF0444A in Combination With Carboplatin, Paclitaxel and Bevacizumab in Patients With Advanced or Recurrent Non-Squamous Non-Small Cell Lung Cancer Who Have Not Received Prior Chemotherapy for Advanced Disease (NILE)

NCT01366131
View directory record Official record
Conditions
Non-Squamous Non-Small Cell Lung Cancer
Interventions
MEGF0444A, bevacizumab, carboplatin, paclitaxel, placebo
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2011
U.S. locations
20
States / cities
Birmingham, Alabama • Hot Springs, Arkansas • Santa Monica, California + 17 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2016 · Synced Oct 23, 2026, 3:33 AM EDT
Completed Phase 2 Interventional

Efficacy and Safety Study of Magnesium Iron Hydroxycarbonate for the Reduction of High Blood Phosphate in Hemodialysis Patients

NCT00317694
View directory record Official record
Conditions
Chronic Kidney Failure
Interventions
Fermagate, Placebo
Drug
Lead sponsor
Ineos Healthcare Limited
Industry
Eligibility
18 Years and older
Enrollment
111 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
4
States / cities
Pine Bluff, Arkansas • Stuttgart, Arkansas • Charlotte, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 10, 2009 · Synced Oct 23, 2026, 3:33 AM EDT
Completed Phase 2 Interventional

Study of the Efficacy and Safety of NST-1024 Versus Placebo in Subjects With Hypertriglyceridemia

NCT05889156
View directory record Official record
Conditions
High Triglycerides
Interventions
NST-1024, Placebo
Drug · Other
Lead sponsor
NorthSea Therapeutics B.V.
Industry
Eligibility
18 Years to 79 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
31
States / cities
Birmingham, Alabama • Daphne, Alabama • Tempe, Arizona + 28 more
Source: ClinicalTrials.gov public record
Updated Apr 24, 2025 · Synced Oct 23, 2026, 3:33 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

A Study to Evaluate the Safety and Immunogenicity of GlaxoSmithKline Biologicals' Influenza Vaccine GSK3206641A Administered in Adults 18 to 64 Years of Age and 65 Years of Age and Older

NCT04789577
View directory record Official record
Conditions
Influenza, Human
Interventions
FLU-Q-PAN H7N9 Formulation 1, FLU-Q-PAN H7N9 Formulation 2, FLU-Q-PAN H7N9 Formulation 3, AS03B, AS03A, Placebo
Biological · Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
833 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
8
States / cities
Stockbridge, Georgia • Meridian, Idaho • Cary, North Carolina + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 10, 2023 · Synced Oct 23, 2026, 3:33 AM EDT
Completed Not applicable Interventional

The Clinic Treatment Project

NCT01178554
View directory record Official record
Conditions
Anxiety, Depression, Problem Behavior
Interventions
psychotherapy, evidence-based treatment, modular evidence-based treatment
Behavioral
Lead sponsor
Judge Baker Children's Center
Other
Eligibility
7 Years to 13 Years
Enrollment
203 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
2
States / cities
Honolulu, Hawaii • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 16, 2011 · Synced Oct 23, 2026, 3:33 AM EDT
Completed Phase 4 Interventional Results available

Aliskiren and Valsartan vs Valsartan Alone in Patients With Stage II Systolic Hypertension and Type II Diabetes Mellitus

NCT00927394
View directory record Official record
Conditions
Hypertension
Interventions
Aliskiren, Valsartan, Placebo for Aliskiren, Placebo for Valsartan
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years and older
Enrollment
1,143 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
4
States / cities
Newark, Delaware • Kansas City, Missouri • Camden, New Jersey + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 6, 2012 · Synced Oct 23, 2026, 3:33 AM EDT
Completed Phase 2 Interventional Results available

A Study of Definitive Therapy to Treat Prostate Cancer After Prostatectomy

NCT03043807
View directory record Official record
Conditions
Prostate Cancer
Interventions
Leuprolide Acetate, Docetaxel, Bicalutamide, Radiation, Abiraterone Acetate
Drug · Radiation
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years to 80 Years · Male only
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 16, 2023 · Synced Oct 23, 2026, 3:33 AM EDT
Completed Phase 4 Interventional Results available

The PIO II Study: In-office Post-op Placement of a Steroid-eluting Sinus Implant

NCT02668302
View directory record Official record
Conditions
Chronic Sinusitis, Ethmoidal
Interventions
Steroid-eluting sinus implant, Post-op standard of care
Combination Product · Other
Lead sponsor
Collin County Ear Nose & Throat
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Frisco, Texas
Source: ClinicalTrials.gov public record
Updated Oct 12, 2018 · Synced Oct 23, 2026, 3:33 AM EDT
Completed Not applicable Interventional Results available

Parent Nurse Controlled Analgesic in Pediatric Patients With Developmental Delay

NCT00743730
View directory record Official record
Conditions
Post Operative Pain
Interventions
Pain and standard side effect management for PNCA with basal method., Pain and standard side effect management with PNCA without basal, Pain and standard side effect management with IV on an as needed basis method.
Other
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
4 Years to 18 Years
Enrollment
94 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Aug 28, 2019 · Synced Oct 23, 2026, 3:33 AM EDT
Recruiting Not applicable Interventional

MRI-Based Machine Learning Approach Versus Radiologist MRI Reading for the Detection of Prostate Cancer, The PRIMER Trial

NCT07162194
View directory record Official record
Conditions
Prostate Carcinoma
Interventions
Targeted Prostate Biopsy, Prostate Imaging Reporting & Data System, Deep Learning Artificial Intelligence, Green Learning Artificial Intelligence, Radical Prostatectomy
Procedure · Diagnostic Test
Lead sponsor
University of Southern California
Other
Eligibility
20 Years and older · Male only
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Sep 1, 2026 · Synced Oct 23, 2026, 3:33 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Live Attenuated ETEC Vaccine ACE527 With and Without dmLT Adjuvant in Adults

NCT01739231
View directory record Official record
Conditions
Diarrhea
Interventions
ACE527, dmLT, CeraVacx placebo, H10407 challenge strain
Biological
Lead sponsor
PATH
Other
Eligibility
18 Years to 50 Years
Enrollment
81 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2014
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 12, 2019 · Synced Oct 23, 2026, 3:33 AM EDT
Completed Phase 3 Interventional Results available

Eflornithine and Sulindac in Preventing Colorectal Cancer in Patients With Colon Polyps

NCT00118365
View directory record Official record
Conditions
Precancerous Condition
Interventions
placebo, eflornithine, sulindac, laboratory biomarker analysis
Other · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
40 Years to 80 Years
Enrollment
375 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2008
U.S. locations
1
States / cities
Orange, California
Source: ClinicalTrials.gov public record
Updated Jan 22, 2015 · Synced Oct 23, 2026, 3:33 AM EDT
Completed Phase 2 Interventional Results available

Antifibrotic Activity Of GI262570 In Chronic Hepatitis C Subjects

NCT00244751
View directory record Official record
Conditions
Cirrhosis, Liver
Interventions
GI262570 0.5 mg, GI262570 1.0 mg, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years to 70 Years
Enrollment
265 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
58
States / cities
Birmingham, Alabama • Tucson, Arizona • North Little Rock, Arkansas + 45 more
Source: ClinicalTrials.gov public record
Updated Dec 11, 2017 · Synced Oct 23, 2026, 3:33 AM EDT
Completed Phase 2 Interventional Results available

Aldesleukin With or Without Vaccine Therapy in Treating Patients With Stage IV Melanoma

NCT00726739
View directory record Official record
Conditions
Stage IV Melanoma
Interventions
aldesleukin, allogeneic large multivalent immunogen vaccine
Biological
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 28, 2017 · Synced Oct 23, 2026, 3:33 AM EDT
Completed Phase 2 Interventional Results available

Combination Chemotherapy With or Without Vismodegib in Treating Patients With Advanced Stomach Cancer or Gastroesophageal Junction Cancer

NCT00982592
View directory record Official record
Conditions
Adenocarcinoma of the Gastroesophageal Junction, Adenocarcinoma of the Stomach, Recurrent Gastric Cancer, Stage IIIA Gastric Cancer, Stage IIIB Gastric Cancer, Stage IIIC Gastric Cancer, Stage IV Gastric Cancer
Interventions
oxaliplatin, leucovorin calcium, fluorouracil, placebo, vismodegib, laboratory biomarker analysis
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
30
States / cities
Sacramento, California • Chicago, Illinois • Decatur, Illinois + 16 more
Source: ClinicalTrials.gov public record
Updated Jan 25, 2016 · Synced Oct 23, 2026, 3:33 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Trial of Testosterone Undecanoate for Optimizing Performance During Military Operations

NCT04120363
View directory record Official record
Conditions
Caloric Restriction, Exercise, Sleep
Interventions
Testosterone Undecanoate, Sesame Oil
Drug
Lead sponsor
Pennington Biomedical Research Center
Other
Eligibility
18 Years to 35 Years · Male only
Enrollment
34 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
1
States / cities
Baton Rouge, Louisiana
Source: ClinicalTrials.gov public record
Updated Oct 7, 2022 · Synced Oct 23, 2026, 3:33 AM EDT
Completed Phase 2 Interventional

Safety and Efficacy Study of Fipamezole in Treatment of Motor Dysfunctions in Parkinson's Disease

NCT00559871
View directory record Official record
Conditions
Parkinson's Disease
Interventions
fipamezole
Drug
Lead sponsor
Juvantia Pharma Ltd
Industry
Eligibility
30 Years and older
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
29
States / cities
Birmingham, Alabama • Northport, Alabama • Tucson, Arizona + 25 more
Source: ClinicalTrials.gov public record
Updated Jun 3, 2009 · Synced Oct 23, 2026, 3:33 AM EDT
Not listed Phase 2 Interventional Accepts healthy volunteers

Study to Assess the Clinical Benefit and Safety of Droxidopa in Parkinson's Disease

NCT02066571
View directory record Official record
Conditions
Parkinson's Disease, Freezing of Gait, Cognitive Ability, General
Interventions
Droxidopa, sugar pill
Drug
Lead sponsor
Henry Ford Health System
Other
Eligibility
30 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
2
States / cities
Chicago, Illinois • West Bloomfield, Michigan
Source: ClinicalTrials.gov public record
Updated Nov 3, 2016 · Synced Oct 23, 2026, 3:33 AM EDT
Completed Phase 2 Interventional Results available

Cellcept for Treatment of Juvenile Neuronal Ceroid Lipofuscinosis

NCT01399047
View directory record Official record
Conditions
Juvenile Neuronal Ceroid Lipofuscinosis
Interventions
Mycophenolate mofetil, Liquid Placebo
Drug
Lead sponsor
University of Rochester
Other
Eligibility
6 Years to 25 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated May 21, 2019 · Synced Oct 23, 2026, 3:33 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Examining How a Text Message-based Educational Intervention Influences COVID-19 Testing

NCT07074171
View directory record Official record
Conditions
COVID-19 Testing Behaviors
Interventions
Text message-based education intervention, Historical Control
Behavioral · Other
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years to 89 Years
Enrollment
384 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
3
States / cities
Brownsville, Texas • Houston, Texas • Tyler, Texas
Source: ClinicalTrials.gov public record
Updated Jan 6, 2026 · Synced Oct 23, 2026, 3:33 AM EDT
Completed Phase 3 Interventional Results available

Gabapentin Compared to Standard of Care in Preventing Mucositis in Patients With Stage III-IV Head and Neck Cancer Undergoing Primary or Adjuvant Chemoradiation Therapy

NCT02480114
View directory record Official record
Conditions
Malignant Head and Neck Neoplasm, Mucositis, Radiation-Induced Disorder
Interventions
Educational Intervention, Gabapentin, Pain Therapy, Quality-of-Life Assessment, Questionnaire Administration, Oxycodone/Acetaminophen, Hydrocodone/Acetaminophen, Fentanyl, Ibuprofen, Magic Mouthwash
Other · Drug
Lead sponsor
Vanderbilt-Ingram Cancer Center
Other
Eligibility
21 Years and older
Enrollment
79 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Feb 18, 2021 · Synced Oct 23, 2026, 3:33 AM EDT
Completed No phase listed Observational

Echocardiographic Risk Factors of Stroke in Patients With Atrial Fibrillation

NCT03824509
View directory record Official record
Conditions
Atrial Fibrillation, Stroke
Interventions
Chart Review
Other
Lead sponsor
MaineHealth
Other
Eligibility
Not listed
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Rockport, Maine
Source: ClinicalTrials.gov public record
Updated Jul 16, 2021 · Synced Oct 23, 2026, 3:33 AM EDT
Recruiting Phase 1Phase 2 Interventional

A Safety and Efficacy Study of a One-time Intravitreal Injection of SAR446597 in Participants With Geographic Atrophy Secondary to Age-related Macular Degeneration

NCT07215234
View directory record Official record
Conditions
Geographic Atrophy
Interventions
SAR446597, Sham Comparator
Drug
Lead sponsor
Sanofi
Industry
Eligibility
60 Years and older
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2032
U.S. locations
31
States / cities
Peoria, Arizona • Scottsdale, Arizona • Beverly Hills, California + 25 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2026 · Synced Oct 23, 2026, 3:33 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Phase I/II Study of SRP-4053 in DMD Patients

NCT02310906
View directory record Official record
Conditions
Duchenne Muscular Dystrophy
Interventions
Placebo, SRP-4053
Drug
Lead sponsor
Sarepta Therapeutics, Inc.
Industry
Eligibility
6 Years to 15 Years · Male only
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 19, 2020 · Synced Oct 23, 2026, 3:33 AM EDT